Rituximab Selectively Suppresses Specific Islet Antibodies

OBJECTIVE: The TrialNet Study Group evaluated rituximab, a B-cell–depleting monoclonal antibody, for its effect in new-onset patients with type 1A diabetes. Rituximab decreased the loss of C-peptide over the first year of follow-up and markedly depleted B lymphocytes for 6 months after administratio...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Liping, Herold, Kevan, Krause-Steinrauf, Heidi, McGee, Paula L., Bundy, Brian, Pugliese, Alberto, Krischer, Jeff, Eisenbarth, George S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2011
Materias:
Immunology and Transplantation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178300/
https://www.ncbi.nlm.nih.gov/pubmed/21831969
http://dx.doi.org/10.2337/db11-0674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3178300/
https://www.ncbi.nlm.nih.gov/pubmed/21831969
http://dx.doi.org/10.2337/db11-0674

Ejemplares similares